Shipping Embryos Created Abroad to the USA for Surrogacy Using Retrospective FDA Compliance via Manhattan and a Toronto Option

AI Smart Summary

Executive summary

Many intended parents in Europe and China already have embryos frozen at overseas IVF clinics that are not registered with the U.S. FDA as HCT/P establishments—and then discover that many U.S. IVF clinics will not accept (or will not transfer) those embryos into a gestational carrier due to FDA donor-eligibility and import-compliance risk. Under U.S. law, embryos and other reproductive tissues intended for transfer into a recipient are regulated as HCT/Ps and generally require donor screening + donor testing + a donor-eligibility determination for the semen and oocyte donors.

Surrogacy4All’s service offering (as described here) is a structured “FDA remediation / retrospective compliance” pathway coordinated through a Manhattan IVF clinic that is FDA-registered (HCT/P establishment registration) and experienced in reviewing international records, arranging compliant donor screening/testing where feasible, and managing U.S. import steps. FDA rules also contain narrow exceptions that can allow use of certain embryos even when the “ideal” donor-eligibility record was not completed at the time the embryo was created—but those exceptions come with mandatory labeling and do not “erase” compliance deficiencies, which is one reason U.S. clinics often remain cautious.

Key regulatory realities to be transparent about.
FDA compliance is not just “clinic registration.” It is about (1) donor screening/testing requirements, (2) timing windows for specimen collection around gamete recovery, (3) required labeling in specific exception scenarios, and (4) import admissibility steps when an HCT/P is offered for import.

Canada option (Toronto).
For some families, a Toronto clinic working under Health Canada’s assisted human reproduction framework can be an alternative pathway—either to pursue family-building in Canada (noting Canada’s prohibition on paying a surrogate and restrictions involving intermediaries), or as a logistics/clinical alternative when U.S. clinic acceptance is not feasible.

Important disclaimer language.
This article is general information and not legal or medical advice. Rules differ based on embryo origin, donor type, documentation, and local export law. Final acceptance always depends on the receiving clinic’s medical director and tissue-compliance review, and U.S. import decisions depend on FDA/CBP processes at the port of entry.

What This Page Covers

This post is designed for overseas intended parents (Europe + China) who already have embryos frozen abroad and want a U.S.-based gestational carrier journey but are facing “our clinic won’t accept the embryos” problems. It covers:

A practical, compliance-first roadmap

• What U.S. FDA rules actually require for embryos used with a gestational carrier (and why clinics say “no”)
• A step-by-step “FDA remediation / retrospective compliance” workflow, including legal, medical, donor testing, documentation, courier logistics, customs/FDA clearance, and clinic acceptance
• Eligibility and failure points (what makes cases succeed or collapse)
• Timing windows for testing and documentation (what must happen early to avoid losing months)

Pricing transparency

• Two detailed pricing tables—Europe → Manhattan and China → Manhattan—with itemized ranges and contingency planning (USD)

Decision support

• Recommended workflows and a decision-tree flowchart (Mermaid)
• A Canada/Toronto option section (Health Canada framework + practical considerations)

FDA and Import Compliance Overview

Why U.S. clinics often refuse embryos created at non‑FDA-registered overseas clinics.
When embryos are transferred into a gestational carrier, the carrier is regulated as the HCT/P recipient, and the semen and oocyte providers are treated as donors for donor-eligibility purposes. FDA guidance is explicit that gestational/surrogate carriers are not donors and that donor-eligibility determinations are tied to the oocyte and semen donors (and must be analyzed relative to the gestational carrier/recipient relationship).

Core FDA donor-eligibility requirements that usually drive “clinic refusal.”

• Donor screening: establishments performing donor screening must review the donor’s relevant medical records for risk factors/clinical evidence of specified communicable disease agents and diseases; reproductive donors also require screening for risk factors/clinical evidence of genitourinary tract infections.
• Donor testing: testing must include HIV-1, HIV-2, HBV, HCV, and Treponema pallidum (syphilis). Reproductive donors must also be tested for Chlamydia trachomatis and Neisseria gonorrhea (unless recovery method ensures freedom from contamination).
• Test method + lab requirements: donor testing must use FDA-licensed/approved/cleared donor screening tests and must be performed by a CLIA-certified laboratory (or equivalent as determined by CMS).
• Timing windows: donor specimen collection for testing is generally required at recovery or within 7 days before/after recovery, with specific exceptions (including oocytes up to 30 days before recovery).

If embryos were created abroad without U.S.-style donor eligibility documentation and timing, a receiving U.S. clinic may conclude it cannot safely document compliance—especially if an anonymous donor is involved, because FDA guidance illustrates that use of reproductive material from an ineligible anonymous donor is prohibited.

What “retrospective FDA compliance / FDA remediation” can and cannot mean (set expectations).
FDA rules contain exceptions that can allow use of certain embryos even when donor eligibility requirements were not met at the time of creation (for example, embryos originally intended for a specific individual/couple that are later intended for directed/anonymous donation). However, the regulation also states that nothing in that exception “creates an exception for deficiencies” in donor eligibility determinations or the performance of donor screening/testing. Practically, many clinics still require robust “remediation packets” (updated screening/testing + records + labeling) to manage risk and satisfy internal compliance policies.

Import rules that matter for embryo shipments.
When an HCT/P is offered for import, the importer of record must notify FDA and provide sufficient information (including via CBP’s ACE system) so FDA can make an admissibility decision. The HCT/P must be held intact pending that decision, though it may be moved under quarantine to the consignee while FDA reviews documentation.
Separately, FDA’s import program explains that for HCT/Ps, entry review commonly involves verifying HCT/P establishment registration and an HCT/P affirmation of compliance with 21 CFR Part 1271, and that inaccurate/incomplete entry data can delay review or trigger detention.
CBP has issued operational guidance noting that many biological material shipments arrive with missing/conflicting documentation and emphasizing accurate description, proper labeling/packaging/declaring, and having required documents (permits/letters/health certificates/invoices) ready—noncompliant imports may be refused/denied entry.

Step-by-Step Process for Retrospective FDA Compliance and Import

Step zero: intake and feasibility (1–5 business days).

1. Collect embryo details: clinic name/country, vitrification method, number of embryos, storage tank ID, and complete lab records if available.
2. Identify all genetic contributors: intended parents vs donor egg/sperm; directed vs anonymous.
3. Confirm destination plan: U.S. gestational carrier transfer (Manhattan clinic) vs Canada/Toronto alternative.

Step one: choose the receiving clinic early (the gate that controls everything).
A Manhattan IVF clinic that is FDA-registered as an HCT/P establishment should perform an upfront compliance review and issue a conditional acceptance list (required documents, required testing, labeling plan, chain-of-custody requirements). FDA provides public mechanisms to look up HCT/P establishment registration, and FDA rules require establishments to register/list their HCT/Ps.
Clinic-specific (must list as “varies”): receiving/handling fees, storage billing partner, transfer protocols, and internal compliance thresholds.

Step two: legal coordination (parallel track; don’t wait).

• Confirm that your surrogacy attorney and the clinic agree on how the embryos will be labeled/described (directed donation to a gestational carrier; donor relationships) because donor classification affects compliance steps.
• Confirm consent and custody documents. (For Canada pathways, written consent is a central statutory theme: donors must provide written consent before embryos/reproductive material is used for any purpose.)

Step three: donor eligibility “remediation packet” (medical + testing + documentation).
This is the core deliverable that often turns a “no” into a “yes,” even when embryos were created abroad.

A. Donor screening (records + interview).
Under 21 CFR 1271.75, donor screening requires review of medical records for risk factors/clinical evidence of specified infections (and reproductive donors require additional genitourinary screening).
Operationally, FDA training materials emphasize a documented donor medical history interview, often performed within a defined period, and note it may occur in person or by telephone.

B. Donor testing (CLIA + FDA-labeled donor screening assays).
Under 21 CFR 1271.85, required testing includes HIV-1, HIV-2, HBV, HCV, and syphilis; reproductive donors must also include Chlamydia trachomatis and Neisseria gonorrhea.
Under 21 CFR 1271.80, tests must use FDA-licensed/approved/cleared donor screening tests and be performed by a CLIA-certified laboratory (or equivalent).
Many U.S. donor/banking programs operationalize this as “testing must be completed within 7 days of each collection” for directed semen donors, consistent with FDA materials.

C. Timing reality check (and how exceptions are used).
If original testing timing windows were not met at the time embryos were created abroad, you cannot retroactively change that fact. What you can do is:

• Determine whether your embryo fits an FDA exception pathway that allows use with required labeling and disclosures; and
• Perform “when possible” screening/testing before transfer (language FDA uses in its exceptions/labeling framework).

D. Required labeling/disclosure plan (often the clinic’s compliance linchpin).
FDA’s exception and labeling rule includes required phrases such as “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” unless all applicable screening/testing was performed, “WARNING: Advise recipient of communicable disease risks” in specified circumstances, and a specific statement to advise recipients when screening/testing was not performed at the time of recovery/cryopreservation but was performed subsequently.
This labeling concept is a major reason a compliance-capable receiving clinic is essential.

Step four: courier selection and shipping design (chain-of-custody + temperature control).
Choose a cryo-courier that can support:

• A validated liquid nitrogen dry shipper (example: material stored below -150°C; dry shipper holding time may be up to ~10 days depending on equipment),
• Temperature monitoring and international documentation assistance.

Cryoport’s published FAQs, for example, describe dry shippers validated below -150°C and a holding time up to 10 days, plus integrated tracking/temperature monitoring and assistance generating shipping paperwork (including customs documents).
(Do not represent any vendor’s capabilities as universal; many vendors exist.)

Step five: export-side compliance (Europe vs China).

Europe (generalized; country-by-country rules apply).
Europe has a well-developed regulatory framework for tissues and cells; the EU Tissues and Cells Directive sets standards for donation/procurement/testing/processing/storage/distribution and addresses import/export at the EU governance level (implementation varies by country).
Example (UK): the UK regulator (HFEA) states that eggs/sperm/embryos can be moved into/out of the UK provided the import/export is to or from an HFEA-licensed clinic.
Practical impact: expect consent forms, clinic letters/authorizations, and sometimes regulator approvals depending on the country.

China (high scrutiny; feasibility must be validated early).
China has tightened enforcement against illegal ART-related activity, including illegal trade involving gametes/zygotes/embryos and illegal surrogacy-related practices.
In parallel, China’s “human genetic resources” (HGR) compliance regime restricts cross-border transfer of genetic materials; major law firms report restrictions on transferring genetic material and related data out of China since 2019, with implementing rules and ongoing updates (this is not embryo-specific advice; it signals regulatory complexity and risk).
Practical impact: shipping embryos from mainland China can be delayed or impossible depending on clinic policy and applicable approvals; plan for longer lead times and obtain China-qualified legal guidance.

Step six: U.S. customs + FDA admissibility clearance.
Operationally, the importer of record (often the courier or receiving clinic’s broker) should:

• Notify FDA and provide required information through ACE or other authorized electronic systems, and
• Hold the shipment intact pending FDA’s admissibility decision (with possible quarantine transport to the clinic).
  CBP’s operational guidance stresses accurate description of biological shipments and having required documents (permits, letters, health certificates, invoices) ready—noncompliant shipments may be refused/denied entry.
  FDA’s import overview notes that correct entry declarations and relevant “affirmations of compliance” support faster review, while inaccurate/incomplete information may delay review or lead to detention.

Step seven: Manhattan clinic intake + transfer cycle.

• Clinic intake: verifies seals/identifiers, reviews temperature log, transfers to long-term storage, and completes internal compliance sign-off. (Clinic-specific.)
• Transfer cycle: frozen embryo transfer (FET) into the gestational carrier. As one Manhattan-based clinic (NYU Langone Fertility Center) publicly lists, an FET procedure “starts at $5,500” and includes ultrasound monitoring, embryo thaw/prep, and embryo transfer.

Recommended decision-tree workflow (Mermaid).

flowchart TD
  A[Start: Embryos stored overseas] --> B{Are all genetic contributors identifiable and reachable?}
  B -- No --> B1[High risk of non-acceptance; consider: create new embryos in US/Canada or different plan]
  B -- Yes --> C{Was embryo originally created for a specific individual/couple (not an anonymous embryo donation scenario)?}
  C -- No/Unclear --> C1[Clinic compliance review required; may be declined]
  C -- Yes --> D[Pre-review by Manhattan FDA-registered IVF clinic: required docs + labeling plan]
  D --> E{Can donor screening/testing be performed in CLIA-certified lab using FDA-labeled donor screening assays?}
  E -- Yes --> F[Build remediation packet: screening + testing + records]
  E -- No --> E1[Assess exception pathways and clinic policy; consider Canada option or new embryos]
  F --> G{Export jurisdiction}
  G --> H[Europe: EU/UK clinic authorizations + consents]
  G --> I[China: validate legality + approvals early; longer lead time]
  H --> J[Select cryo-courier + shipper + chain-of-custody]
  I --> J
  J --> K[US import: importer of record notifies FDA; CBP docs; FDA admissibility decision]
  K --> L[Manhattan clinic intake + storage]
  L --> M[Gestational carrier medical prep + FET]
  M --> N[Pregnancy monitoring + next steps]

Eligibility, Failure Points, and Time Windows

Eligibility criteria (what usually makes cases workable).

1. Directed, identifiable donors. You can identify and screen/test the semen and oocyte donors (and any donor egg/sperm providers). FDA guidance treats gestational carriers as recipients and focuses donor eligibility on semen/oocyte donors.
2. Sufficient records from the overseas lab. At minimum: embryo creation date, cryopreservation method, storage conditions, identifiers, and chain-of-custody release documents (clinic-specific requirement but nearly universal in practice).
3. A receiving Manhattan clinic willing to accept and document the case. FDA import rules assume a compliant “importer/consignee” structure; clinics that refuse usually do so because they cannot document donor eligibility/labeling and manage compliance exposure.
4. Export feasibility in the originating jurisdiction. Europe often has clearer pathways through licensed clinics; China frequently requires more feasibility work due to enforcement environment and cross-border genetic material controls.

Common failure points (what causes a “dead end”).

• Anonymous donor involvement with missing compliant records. FDA guidance examples show that when a donor is anonymous (not known to the recipient) and is ineligible, use may be prohibited, which makes remediation difficult if you cannot re-contact the donor.
• Inability to meet CLIA/FDA assay requirements. Donor testing must be done using FDA-licensed/approved/cleared donor screening tests and performed by a CLIA-certified lab (or equivalent). If intended parents cannot access this testing pathway (e.g., location constraints), the remediation packet may fail clinic review.
• Timing mismatch (the “you can’t time-travel” problem). The baseline rule requires specimen collection at recovery or within 7 days of recovery (with specific exceptions such as oocytes up to 30 days). When embryos were created years ago without compliant timing, acceptance depends heavily on whether an exception/labeling pathway and clinic policy can address the gap.
• Customs/FDA clearance delays beyond shipper capability. Some shippers are designed for extended hold time (e.g., up to ~10 days for a Cryoport Express shipper per published materials), but clearance delays can still create operational risk if documentation is incomplete.
• China export blocks. Enforcement action targeting illegal ART and restrictions around cross-border transfer of human genetic materials can prevent export entirely in some cases.

Critical time windows

• FDA specimen timing concept: Generally, donor specimen collection must occur at recovery or within 7 days before/after recovery; for oocytes, collection may be up to 30 days before recovery.
• Directed semen donor operational timing: FDA training materials emphasize directed semen donors must be tested within 7 days of collection, and quarantine/retesting is not required for directed donors (it applies to anonymous semen donors).
• Medical history interview documentation: FDA training materials describe donor medical history interviews as documented dialogues and note they may occur by phone; plan scheduling early, especially when donors are abroad.
• Lab specimen handling constraints: specimen guides used in donor screening workflows can impose acceptance limits; for example, a ViroMed specimen guide states frozen samples stored longer than 6 months after collection may not be accepted unless otherwise specified in the package insert—this matters if you try to use “old blood” instead of drawing new specimens.

Pricing and Budget Scenarios

All prices below are estimates in USD intended for budgeting; actual quotes vary by clinic, courier route, permit needs, and case complexity. Importantly, FDA/CBP rules require accurate documentation and entry data; “cutting corners” can create delays, refusals, or repeat shipments.

Europe/Asia to Manhattan estimated pricing